08 / Pharmacology
What the literature reports after a compound is discontinued
Reference documentation on how these compounds are regulated, supplied and studied. Not a vendor assessment, not a recommendation, and not personal-use instructions.
For the compounds where controlled withdrawal data exists, which is essentially the GLP-1 receptor agonists, the effect does not persist. A 2026 systematic review and meta-analysis in the BMJ covering 37 studies and 9,341 participants found weight regain after stopping weight management medication averaging 0.4 kg per month, and projected all measured cardiometabolic markers to return to baseline within 1.4 years. That is the expected result for a compound whose effect depends on continuous receptor occupancy. It is not a general statement about peptides, and the compounds acting by a structural rather than a signalling mechanism have not been studied this way at all.
The randomized withdrawal evidence
SURMOUNT-4 is the cleanest design on this question, because withdrawal was randomized rather than observed. After a 36-week open-label lead-in on tirzepatide producing a mean 20.9 per cent weight reduction, 670 participants were randomized either to continue or to switch to placebo for a further 52 weeks. Those who continued lost a further 5.5 per cent. Those switched to placebo regained 14.0 per cent, a difference of 19.4 percentage points (95 per cent confidence interval 17.7 to 21.2). A later post hoc analysis of the same trial reported that withdrawal produced 25 per cent or greater regain in most participants within a year, with a corresponding reversal of the cardiometabolic improvements.
The pooled picture
The BMJ review pooled 37 studies across 63 intervention arms, with an average treatment duration of 39 weeks and average post-cessation follow-up of 32 weeks. Regain averaged 0.4 kg per month (95 per cent confidence interval 0.3 to 0.5) and was faster after drug treatment than after a behavioural weight management programme by 0.3 kg per month, independent of how much weight had been lost initially. The review concluded that cessation is followed by rapid regain and reversal of the cardiometabolic benefit.
The result is not uniform
A two-year observational follow-up of 25 women with polycystic ovary syndrome who received semaglutide 1.0 mg for 16 weeks on top of continued metformin found weight two years after semaglutide was stopped at 95 kg against a pre-treatment 101 kg, a net reduction that remained statistically significant, with 21 of the 25 still below their starting weight. The study is small, observational, and confounded by continued metformin and lifestyle intervention, so it does not contradict the randomized data. It does show that the trajectory after withdrawal is not fixed.
Why mechanism decides the answer
A compound whose effect requires continuous receptor agonism produces an effect that lasts as long as the agonism does. Once cleared, the receptor signalling it was driving returns to baseline and so does the physiology, which is what the trials above measure. A compound acting by inducing a durable structural change, such as collagen deposition, has a different profile in principle. In practice almost none of the non-approved compounds in this catalog have been studied through a withdrawal period at all, so for those the honest answer is that nobody has measured it.
Frequently asked questions
Do peptides stop working after you stop taking them?
For the GLP-1 receptor agonists, where randomized withdrawal data exists, the effect does not persist. In SURMOUNT-4, participants randomized to placebo after 36 weeks of tirzepatide regained 14.0 per cent of body weight over the following 52 weeks while those who continued lost a further 5.5 per cent. A 2026 BMJ systematic review of 37 studies and 9,341 participants found weight regain after cessation averaging 0.4 kg per month, with all measured cardiometabolic markers projected to return to baseline within 1.4 years. This follows from the mechanism rather than from tolerance: the effect depends on continuous receptor occupancy. Most other compounds in this catalog have never been studied through a withdrawal period, so no comparable figure exists for them.
How much weight regain is reported after discontinuation of a GLP-1 receptor agonist?
The pooled figure from a 2026 BMJ systematic review and meta-analysis is 0.4 kg per month (95 per cent confidence interval 0.3 to 0.5) across 37 studies and 9,341 participants. In the randomized SURMOUNT-4 withdrawal design specifically, the placebo arm regained 14.0 per cent of body weight over 52 weeks after tirzepatide was stopped, against a further 5.5 per cent loss in the arm that continued.
Is rebound after stopping the same as the compound losing effectiveness?
No, and the distinction matters. Tolerance means a compound produces less effect at the same exposure over time. What the withdrawal trials measure is different: the compound is no longer present, so the signalling it was driving stops and the physiology returns toward baseline. Reinstating treatment in these trials restores the effect, which is the opposite of what tolerance would predict.
Sources
- West S and others, weight regain after cessation of medication for weight management: systematic review and meta-analysis, BMJ 2026. PMID 41500720, PROSPERO CRD42024532069
- SURMOUNT-4, continued treatment with tirzepatide for maintenance of weight reduction, JAMA 2024. PMID 38078870, ClinicalTrials.gov NCT04660643
- Cardiometabolic parameter change by weight regain on tirzepatide withdrawal, post hoc analysis of SURMOUNT-4, JAMA Internal Medicine 2026. PMID 41284285
- Maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin, Frontiers in Endocrinology 2024. PMID 38665260
Open this guide on PeptideHelper.org for the interactive version with the full guide series navigation.